Fig. 2: Monitoring of MRD and clonal haematopoiesis in BM of patients treated by venetoclax combination therapy.

a Quantification of LAIP-MRD at first BM assessment after the beginning of treatment (after C1 (n = 9), after C2 (n = 2) or after C3 (n = 1)). Red points indicate patients who did not achieved CR/CRi. The Gray zone on the graph indicates the limit of quantification (0.1%). b Quantification of LSCs-MRD at first BM assessment after the beginning of treatment (after C1 (n = 10), after C2 (n = 3) or after C3 (n = 1)). Red points indicate patients who did not achieved CR/CRi. The Gray zone on the graph indicates the limit of quantification (0.01%). Follow up of MRD by MFC for patients who achieved CR/Cri without (group 1; n = 6) (c) or with relapse at any time during the study (group 2; n = 7) (d). A positive MRD was attested if either or both LAIP-MRD and/or a LSCs-MRD were detected above the limit of quantification. e Median response duration for all patients who achieved CR/CRi according their MRD status (either LAIP-MRD and/or LSCs-MRD) during the follow-up under treatment (always negative or at least one time positive). Follow-up of VAF mutations detected by HTS at different time points during therapy for patients who achieved CR/Cri without (group 1; n = 7) (f) or with relapse at any time during the study (group 2; n = 9) (g). Gray bars indicate mutations whose VAF only slightly decreased or increased during follow-up. Red bars indicates mutations whose VAF increased under therapy. Blue bars indicates mutations whose VAF strongly (at least 70% of decrease) decreased during treatment.